Page 121 - Haematologica-April 2018

CD83 and Hodgkin lymphoma
19. Sorg UR, Morse TM, Patton WN, et al. Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. Pathology. 1997;29(3):294-299.
20. Hock BD, Kato M, McKenzie JL, Hart DN. A soluble form of CD83 is released from acti- vated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int Immunol. 2001;13(7):959-967.
21. Dudziak D, Nimmerjahn F, Bornkamm GW, Laux G. Alternative splicing generates puta- tive soluble CD83 proteins that inhibit T cell proliferation. J Immunol. 2005; 174(11):6672-6676.
22. Horvatinovich JM, Grogan EW, Norris M, et al. Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes. J Immunol. 2017;198(6):2286-2301.
23. Doring C, Hansmann ML, Agostinelli C, et al. A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. Mod Pathol. 2014;27(10):1345-1354.
24. Wilson J, Cullup H, Lourie R, et al. Antibody to the dendritic cell surface activation anti- gen CD83 prevents acute graft-versus-host disease. J Exp Med. 2009;206(2):387-398.
25. Seldon TA, Pryor R, Palkova A, et al. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia. 2016;30(3):692-700.
26. Sheets MD, Amersdorfer P, Finnern R, et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A. 1998;95(11):6157-6162.
27. Jones ML, Seldon T, Smede M, et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. J Immunol Methods. 2010; 354(1-2):85-90.
28. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30- monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458-1465.
29. Dudziak D, Kieser A, Dirmeier U, et al. Latent membrane protein 1 of Epstein-Barr
virus induces CD83 by the NF-kappaB sig- naling pathway. J Virol. 2003;77(15):8290- 8298.
30. Hock BD, Haring LF, Steinkasserer A, Taylor KG, Patton WN, McKenzie JL. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res. 2004;28(3):237-241.
31. Kuppers R. The biology of Hodgkin's lym- phoma. NaR Rev Cancer. 2009;9(1):15-27.
32. Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14(8):517-534.
33. Adams HJ, Nievelstein RA, Kwee TC. Systematic review and meta-analysis on the prognostic value of complete remission sta- tus at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Ann Hematol. 2016;95(1):1-9.
34. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lym- phoma patients aged 60 years and older. Blood. 2015;126(26):2798-2804.
35. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lym- phoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221(3):248-263.
36. Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identifica- tion of new players involved in the cross-talk between HRS cells and infiltrating lympho- cytes. Blood. 2008;111(4):2339-2346.
37. Vardhana S, Younes A. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica. 2016;101(7):794-802.
38. Brown R, Kabani K, Favaloro J, et al. CD86+ or HLA-G+ can be transferred via trogocyto- sis from myeloma cells to T cells and are associated with poor prognosis. Blood. 2012;120(10):2055-2063.
39. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111(6):3220-3224.
40. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792.
41. Gause A, Pohl C, Tschiersch A, et al. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood. 1991;77(9):1983-1988.
42. Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol. 1994;12(4):793-797.
43. Su CC, Chiu HH, Chang CC, Chen JC, Hsu SM. CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells. Cancer Res. 2004;64(6):2148-2152.
44. Billing H, Sander A, Susal C, et al. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients. Transpl Int. 2013; 26(3):331-338.
45. Saini D, Ramachandran S, Nataraju A, et al. Activated effector and memory T cells con- tribute to circulating sCD30: potential mark- er for islet allograft rejection. Am J Transplant. 2008;8(9):1798-1808.
46. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol. 1999; 154(6):1685-1691.
47. Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in pri- mary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 2005; 65(13):5516-5519.
48. Plattel WJ, van den Berg A, Visser L, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica. 2012;97(3):410-415.
49. Hock BD, Fernyhough LJ, Gough SM, Steinkasserer A, Cox AG, McKenzie JL. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk Res. 2009;33(8):1089-1095.
50. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171-179.
haematologica | 2018; 103(4)
665